One genetic result can change which medications your Australian Shepherd receives. Here is the documented MDR1 risk, what testing actually costs, and how to compare insurance without mistaking a positive test for an automatic exclusion.
A three-year-old Australian Shepherd developed tremors, agitation and panting after receiving a prescribed deworming medicine at its recommended dose. The dog needed hospitalization and recovered after supportive treatment.
This was a real case published in 2019, not an invented customer story. An important detail: the owner had not been told to follow the product’s fasting instructions and fed the dog before treatment. Genetic testing later found two copies of the MDR1 variant. The authors highlighted both genetic susceptibility and the importance of product instructions. Read the peer-reviewed case report.
Australian Shepherd insurance discussions often start with hip dysplasia or epilepsy. Those risks matter, but MDR1 (also called an ABCB1 variant) creates a different decision: a relatively affordable genetic test can inform medication choices long before an emergency occurs. Insurance, however, generally pays for eligible treatment rather than every preventive screening test. Understanding both sides is more useful than assuming a test is covered—or that every adverse reaction will be.
What MDR1 Does Inside an Australian Shepherd’s Body
The MDR1 gene, more precisely ABCB1, encodes P-glycoprotein. This transporter helps keep certain drugs out of the brain and affects how some drugs move through the body. A particular inherited variant reduces this protection, so susceptible dogs may experience neurological toxicity from some medications at doses other dogs tolerate. Cornell University College of Veterinary Medicine explains that outcomes depend on the medicine, dose and drug combinations—not merely the presence of a gene result.
Possible signs include excessive salivation, wobbliness or ataxia, tremors, unusual sedation, seizures and, in severe cases, respiratory problems. Two variant copies generally confer greater sensitivity, but one copy can also matter. A clear test for this specific variant does not guarantee that a dog will never experience any adverse drug reaction. UC Davis Veterinary Genetics Laboratory.
How a Known Result Changes the Next Prescription
How to Get an MDR1 Test: Price, Sample and Results
Testing usually uses a cheek swab or EDTA blood sample. WSU’s published PrIMe MDR1 PCR listing shows $70 and a laboratory turnaround of 2–7 business days for its listed test schedule, not a guaranteed delivery time to every owner. The WSU test listing explains sample requirements. UC Davis Veterinary Genetics Laboratory lists a $58 single-test price and says turnaround is at least 15 business days. These are different labs with different timelines and charges; shipping or veterinary collection may add to your total.
Ask the lab or vet for a copy showing the dog’s identity and genotype. Results are commonly reported as no variant copies (N/N), one copy (N/MDR1) or two copies (MDR1/MDR1). The label “carrier” can mislead: a one-copy dog may itself be drug-sensitive, not just pass the variant to offspring. UC Davis provides genotype-specific explanations.
What to Do With the Result
Save a digital and printed copy, ask your veterinarian to flag the medical record, and tell any emergency clinic before sedation, anesthesia or parasite treatment. If the dog is positive, request a medication review rather than attempting to create your own forbidden-drug list. WSU offers veterinary pharmacology guidance for drugs and dosing. Washington State University.
Which Medications Actually Need Special Attention?
Drug sensitivity is not a reason to avoid all medication or routine parasite prevention. It is a reason to match a particular medicine, dose and combination to the dog’s test result. These examples are grounded in Washington State University and VCA Animal Hospitals.
| Drug or category | What owners should know | Next step |
|---|---|---|
| Loperamide (Imodium) | WSU advises avoiding it in dogs with the MDR1 variant at doses used to treat diarrhea because of neurological toxicity risk. | Call your veterinarian for safer diarrhea management; do not self-medicate. |
| Ivermectin and related parasite drugs | High or off-label doses may be dangerous, but approved U.S. canine heartworm preventives at labeled doses have been tested and found safe in MDR1 dogs. | Confirm the exact product, labeled dose and any interacting drugs. |
| Some sedatives and opioids | Drugs such as acepromazine and butorphanol can require different planning or dose adjustment. | Share genotype before surgery, imaging or emergency sedation. |
| Selected chemotherapy medicines | Some drugs, including vincristine and doxorubicin, may need specialist consideration. | Ask the treating oncologist to review the result. |
| Combination products and interactions | A medicine that is acceptable alone can pose additional risk in certain combinations. | Give the vet a complete medication and supplement list. |
Heartworm prevention distinction: WSU states that all heartworm products labeled for dogs in the United States have been tested in dogs with the MDR1 variant and found safe at labeled doses. That does not make high-dose ivermectin or every drug combination safe. See the WSU heartworm-prevention guidance. Never change or skip prescribed prevention solely because of an MDR1 result.
What the Published Australian Shepherd Drug-Reaction Case Actually Shows
The 2019 report describes a three-year-old male Australian Shepherd receiving emodepside/praziquantel (Profender) at a recommended dose. The dog was fed shortly before administration despite manufacturer fasting instructions; the owner had not been told those instructions. Tremors, agitation and panting followed, and the dog was hospitalized. After treatment, the neurological signs resolved and the dog was discharged the next day. Genetic testing identified two MDR1 variant copies. 2019 peer-reviewed case report.
That case demonstrates a real drug-sensitivity hazard, but it does not prove that every correctly administered routine dewormer will harm an MDR1-positive dog, that all cases require intensive care, or that a particular insurer paid the bill. It also cannot be used to estimate the frequency of such reactions in the breed.
Recognizing a Possible Drug Reaction: An Emergency Plan
If your dog develops unusual wobbliness, tremors, marked sleepiness, drooling, seizures or breathing difficulty after a medicine, contact an emergency veterinarian immediately. Do not wait to see whether severe signs pass, and do not administer extra medication or induce vomiting unless a veterinary professional directs you.
- Tell the clinic the drug’s name, strength, amount, time given and whether food was involved.
- Bring the package or a photograph of the label, plus a list of other medicines.
- Share the MDR1 laboratory report if you have one; if not, mention Australian Shepherd breed risk.
- Follow the veterinarian’s emergency instructions. Ask about the estimate after urgent stabilization, not before.
- Keep discharge notes and itemized receipts for any later insurance claim.
Do Not Confuse Screening With Treatment
A genetic test can guide safer prescriptions, but it cannot replace a veterinary exam or guarantee that every drug reaction is preventable. If the dog is ill, immediate medical care comes first—regardless of testing or insurance status.
Will Pet Insurance Pay for MDR1 Testing or a Reaction?
These are two separate insurance questions. Preventive genetic screening is often outside a standard accident-and-illness policy unless a specified wellness benefit applies. Treatment for an adverse drug reaction may be eligible under accident or illness coverage, but actual payment depends on policy definitions, waiting periods, exclusions, prior medical signs and claim documentation. No general rule guarantees a reaction is an “accident.”
Critically, an MDR1-positive test result is not the same thing as a prior clinical drug reaction. Insurers may interpret known inherited risks and pre-existing conditions differently. Do not assume that knowing a genotype automatically voids future coverage, or that hiding a test protects it. Ask the insurer for its sample policy and a written explanation of how it handles a positive genetic screen without symptoms.
| Situation | Possible coverage | What to verify |
|---|---|---|
| Healthy puppy gets an MDR1 screening test | Often not under base accident-and-illness; a wellness allowance may apply. | Does the plan specifically reimburse genetic screening? |
| New drug reaction after policy starts | Potentially eligible if all terms are satisfied. | Accident vs illness classification, waiting period, exam fees and exclusions. |
| Reaction or symptoms documented before enrollment | May be excluded as pre-existing or related to prior symptoms. | Exact policy definition and medical-history review. |
| Positive genotype, no symptoms before enrollment | Not automatically the same as a prior clinical reaction. | Ask how genetic findings and future medication toxicity are treated. |
| Emergency hospitalization and follow-up | Potentially eligible for covered care; not every charge is reimbursable. | Annual limit, deductible, reimbursement, exam fees and prescription terms. |
What Does MDR1 Testing Save? A Transparent Cost Example
Rather than publishing unsupported national “typical” hospitalization costs, consider a clearly hypothetical emergency bill of $3,000. With a $500 deductible not yet met, 80% reimbursement and all charges eligible, reimbursement would be ($3,000 − $500) × 80% = $2,000. The owner would pay $1,000, plus any premium or noncovered charges. A policy with excluded exam fees or different deductible ordering could produce a different result.
Compare that with a published $70 WSU MDR1 test or $58 UC Davis test, before additional charges. Testing is not a guarantee that an emergency will never occur, and a hospitalization is not guaranteed to be covered. The useful comparison is that testing supplies actionable information at a known laboratory price, while emergency bills and insurance reimbursement are variable.
Three Questions That Can Prevent a Costly Misunderstanding
Ask the insurer: “Is preventive MDR1 screening eligible for any wellness allowance?” “Does a positive ABCB1 test without symptoms affect later adverse-drug-reaction claims?” and “Which exam fees, drugs and hospitalization charges would be excluded from an otherwise covered reaction?” Request the answers in writing and retain the policy version.
What Australian Shepherd Insurance Costs per Month
There is no universal Australian Shepherd premium. A figure without the dog’s age, ZIP code, annual limit, reimbursement, deductible and policy date is not a reliable shopping comparison. Instead of repeating the original unsourced $35–$65 monthly range as fact, use it only as an example of a possible budget, not a verified breed average.
For meaningful comparisons, request at least three actual quotes on the same day for the same dog. Use the same deductible, reimbursement percentage and annual limit, then record whether examination fees, hereditary conditions, medication and rehabilitation are included. Compare the annual premium as well as the monthly price. Our pet insurance cost calculator can help model the trade-offs, but it is not an insurer quote.
Other Australian Shepherd Risks That Matter When Choosing a Plan
MDR1 is a distinctive medication-safety issue, but it should not crowd out the reasons an Australian Shepherd may need ordinary illness and injury coverage. Review hip dysplasia and other orthopedic conditions, epilepsy or seizure evaluation, and inherited eye conditions with your veterinarian. Ask insurers whether hereditary conditions are eligible, how orthopedic waiting periods work, and whether specialist diagnostics and ongoing medication count toward an annual limit.
Do not assume every Australian Shepherd will develop these conditions, and do not treat a breed risk as a diagnosis. The most useful policy is one that balances the dog’s actual history, your ability to pay an emergency bill and the exclusions you can accept. A plan focused only on accidents may leave chronic neurological or eye conditions outside coverage.
What Australian Shepherd Owners Should Do Now
- Discuss MDR1 testing with your veterinarian. It is particularly useful before a medication of concern is needed. Testing should not delay necessary treatment.
- Store the report permanently. Share it with your primary vet, specialist and emergency hospital; ask them to flag it in the record.
- Review medications, not just a gene label. Use WSU or your veterinarian’s current drug guidance; never stop heartworm prevention without professional advice.
- Compare insurance terms before a crisis. Check genetic-screening benefits, hereditary coverage, exam fees, waiting periods and prior-condition definitions.
- Keep accurate records. Medical notes and a complete drug history help clinicians treat safely and insurers assess claims.
Why This Insurance Gap Matters—and Where the Comparison Ends
Preventive testing and insurance treatment benefits solve different problems. A policy is designed mainly to spread the financial risk of eligible unexpected veterinary care; a screening test helps a veterinarian prevent a specific avoidable hazard. The fact that a plan may reimburse an emergency but not a test does not mean a future reaction is automatically covered. It also does not mean the dog must be untested to qualify.
For an owner, the sensible response is to use the genetic information regardless of reimbursement, then choose insurance based on the broad range of accidents and illnesses the dog might face. That is a stronger decision than judging a policy only by whether it pays for one laboratory test.
Frequently Asked Questions
Usually not under the standard accident-and-illness benefit when testing is preventive screening. Some wellness allowances may reimburse eligible testing, but that depends on the specific policy and add-on. Request the relevant benefit wording before purchase.
It may, if the illness or injury is eligible under the policy and the applicable waiting periods and exclusions have been satisfied. A positive genetic test alone does not necessarily mean a future reaction is excluded, but earlier symptoms, diagnoses and insurer definitions matter. Ask for written clarification.
Washington State University estimates approximately 50% of Australian Shepherds have the variant. This is a breed-level approximate frequency, not a 50% chance that any particular medication will cause a reaction.
Yes. UC Davis and Cornell explain that dogs with one copy may show sensitivity; dogs with two copies are generally at greater risk. The drug, dose, interactions and clinical situation also matter.
There is no single reliable nationwide price for every Australian Shepherd. Premiums depend on age, ZIP code, plan type, annual limit, reimbursement and deductible. Compare actual quotes using identical settings rather than relying on an unsourced breed-wide range.
WSU states that heartworm preventives labeled for dogs in the United States have been tested in dogs with the MDR1 variant and found safe at label doses. High doses, other uses and certain drug combinations require veterinary review.
The Bottom Line on Australian Shepherd Pet Insurance
WSU estimates that about half of Australian Shepherds have the MDR1 variant. A one-time test can give veterinarians useful prescribing information; WSU currently lists its test at $70. The breed’s risk is real, but it is not a reason to fear every routine medicine—approved U.S. heartworm preventives at labeled doses are a particularly important exception.
Look for insurance that explains its hereditary-condition rules, medication and hospitalization benefits, and treatment of positive genetic screens without symptoms. Get the test when your veterinarian recommends it, keep the result accessible and seek care promptly if your dog reacts to medication. For related breed decisions, see our Doberman and Great Dane guides and our editorial information.
Sources
- Washington State University: breed frequencies, medication guidance and veterinary pharmacology consultation.
- WSU MDR1 test listing: published price, sample requirements and laboratory schedule.
- UC Davis Veterinary Genetics Laboratory: genotypes, sensitivity, laboratory price and turnaround.
- 2019 peer-reviewed Australian Shepherd case report: documented drug reaction and clinical circumstances.
- Cornell University College of Veterinary Medicine: MDR1 inheritance and clinical implications.
- WSU heartworm-prevention guidance: labeled heartworm products and dose-specific safety.
- VCA Animal Hospitals: MDR1-related adverse effects and medication considerations.
The PetCoverToday Editorial Team develops and maintains the guides on this site, checking cost figures, coverage terms, and policy rules against insurers' own published pages and, where relevant, veterinary and industry sources. PetCoverToday is an informational website, not a licensed insurance agency, and does not sell policies. Read more about our editorial approach.